A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate‐to‐severe atopic eczema
2019 ◽
Vol 180
(3)
◽
pp. 435-437
◽
2012 ◽
Vol 166
(4)
◽
pp. 701-703
◽
2012 ◽
Vol 166
(4)
◽
pp. 704-704
◽
2012 ◽
Vol 166
(4)
◽
pp. 705-707
◽
2015 ◽
Vol 100
(8)
◽
pp. 803.1-806
2018 ◽
Vol 179
(6)
◽
pp. 1404-1405
◽
2015 ◽
Vol 41
(1)
◽
pp. 45-47
◽
1984 ◽
Vol 59
(10)
◽
pp. 983-986
◽